首页> 外文期刊>Archives of dermatological research. >Recombinant adeno-associated virus type 2-mediated gene transfer into human keratinocytes is influenced by both the ubiquitin/proteasome pathway and epidermal growth factor receptor tyrosine kinase.
【24h】

Recombinant adeno-associated virus type 2-mediated gene transfer into human keratinocytes is influenced by both the ubiquitin/proteasome pathway and epidermal growth factor receptor tyrosine kinase.

机译:重组腺相关病毒2型介导的基因转移到人角质形成细胞中,受遍在蛋白/蛋白酶体途径和表皮生长因子受体酪氨酸激酶的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Efficient gene delivery into keratinocytes is a prerequisite for successful skin gene therapy. Vectors based on recombinant adeno-associated virus type 2 (rAAV-2) offer several promising features that make them attractive for cutaneous applications. However, highly efficient gene delivery may be hampered by different cellular factors, including lack of viral receptors, impairment of cytoplasmic trafficking or limitations in viral second-strand synthesis. This study was undertaken to find factors that influence rAAV-2-mediated in vitro gene transfer into human keratinocytes and, consequently, ways to optimize gene delivery. Transduction experiments using rAAV-2 vectors expressing green fluorescent protein (GFP) demonstrated that impaired cellular trafficking of vector particles and high levels of autophosphorylation at epidermal growth factor receptor tyrosine kinase (EGF-R TK) have a negative influence on gene transfer into keratinocytes. Treatment of keratinocytes with proteasome inhibitor MG132 resulted in a transient augmentation of GFP expression in up to 37% of cells. Treatment with EGF-R TK inhibitors (quinazoline type) enhanced transgene expression in 10-14.5% of the cells. Gene expression was stable for more than 10 weeks and persisted until proliferative senescence occurred. This stable gene expression allows speculation that keratinocyte stem cells have initially been transduced. These findings might have relevance for the use of rAAV-2 vectors in skin gene therapy: transient enhancement of rAAV-2 transduction with proteasome inhibitors might be useful for genetic promotion of wound healing or skin-directed vaccination. Treatment with quinazolines may increase rAAV-2 transduction of keratinocyte stem cells, which is important for gene therapy approaches to inherited diseases.
机译:有效的基因传递到角质形成细胞是成功的皮肤基因治疗的先决条件。基于重组腺相关病毒2型(rAAV-2)的载体具有多种有前途的功能,使其对皮肤应用具有吸引力。但是,高效的基因传递可能会受到不同细胞因素的阻碍,这些因素包括病毒受体缺乏,细胞质运输受损或病毒第二链合成受限。进行了这项研究,以寻找影响rAAV-2介导的体外基因向人角质形成细胞转移的因素,并从而研究优化基因传递的方式。使用表达绿色荧光蛋白(GFP)的rAAV-2载体进行的转导实验表明,载体颗粒的细胞运输受损以及表皮生长因子受体酪氨酸激酶(EGF-R TK)的高水平自磷酸化对基因向角质形成细胞的转移具有负面影响。用蛋白酶体抑制剂MG132处理角质形成细胞可导致多达37%的细胞中GFP表达瞬时增加。用EGF-R TK抑制剂(喹唑啉型)处理可提高10-14.5%的细胞中的转基因表达。基因表达稳定超过10周,并一直持续到发生增生性衰老为止。这种稳定的基因表达使人们推测角质形成细胞干细胞已被初步转导。这些发现可能与rAAV-2载体在皮肤基因治疗中的应用有关:蛋白酶体抑制剂瞬时增强rAAV-2转导可能对伤口愈合或皮肤定向疫苗的遗传促进有用。用喹唑啉治疗可能会增加角质形成细胞干细胞的rAAV-2转导,这对于遗传性疾病的基因治疗方法很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号